Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 15Neoplasm Metastasis 3Hereditary Sensory and Autonomic Neuropathies 3Squamous Cell Carcinoma of Head and Neck 2Hyperglycemia 2Advanced Breast Cancer 2Vascular Malformations 1Triple Negative Breast Neoplasms 1Solid Tumor 1Skin Diseases, Vascular 1Recurrence 1Ovarian Neoplasms 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Hormone Receptor Positive Breast Carcinoma 1Head and Neck Neoplasms 1Genetic Diseases, Inborn 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Exanthema 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Arteriovenous Malformations 1Anatomic Stage III Breast Cancer AJCC v8 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × Alpelisib × Clear all
NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡